The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization
- PMID: 26973523
- PMCID: PMC4773875
- DOI: 10.3389/fphar.2016.00035
The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization
Abstract
Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual consumption has become common among the mestizo populations of South America. Ayahuasca use amongst the indigenous people of the Amazon is a form of traditional medicine and cultural psychiatry. During the last two decades, the substance has become increasingly known among both scientists and laymen, and currently its use is spreading all over in the Western world. In the present paper we describe the chief characteristics of ayahuasca, discuss important questions raised about its use, and provide an overview of the scientific research supporting its potential therapeutic benefits. A growing number of studies indicate that the psychotherapeutic potential of ayahuasca is based mostly on the strong serotonergic effects, whereas the sigma-1 receptor (Sig-1R) agonist effect of its active ingredient dimethyltryptamine raises the possibility that the ethnomedical observations on the diversity of treated conditions can be scientifically verified. Moreover, in the right therapeutic or ritual setting with proper preparation and mindset of the user, followed by subsequent integration of the experience, ayahuasca has proven effective in the treatment of substance dependence. This article has two important take-home messages: (1) the therapeutic effects of ayahuasca are best understood from a bio-psycho-socio-spiritual model, and (2) on the biological level ayahuasca may act against chronic low grade inflammation and oxidative stress via the Sig-1R which can explain its widespread therapeutic indications.
Keywords: addiction medicine; ayahuasca; dimethyltryptamine; diseases of civilization; oxidative stress.
Figures
Similar articles
-
[The potential use of ayahuasca in psychiatry].Neuropsychopharmacol Hung. 2016 Jun;18(2):79-86. Neuropsychopharmacol Hung. 2016. PMID: 27390204 Review. Hungarian.
-
Indigenous healing practice: ayahuasca. Opening a discussion.J Pastoral Care Counsel. 2014 Mar-Jun;68(1-2):6. J Pastoral Care Counsel. 2014. PMID: 25241484
-
Beyond the Psychoactive Effects of Ayahuasca: Cultural and Pharmacological Relevance of Its Emetic and Purging Properties.Planta Med. 2022 Nov;88(14):1275-1286. doi: 10.1055/a-1675-3840. Epub 2021 Nov 18. Planta Med. 2022. PMID: 34794194 Review.
-
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902. Curr Neuropharmacol. 2019. PMID: 29366418 Free PMC article. Review.
-
Basics of the medical use of ayahuasca: physiology of dimethyltryptamine.Lege Artis Med. 2016 Sep-Oct;26(9-10):413. Lege Artis Med. 2016. PMID: 29537778 English, Hungarian.
Cited by
-
Innovative spectrofluorometric method for determination of harmaline and harmine in different matrices.Sci Rep. 2023 Nov 15;13(1):19951. doi: 10.1038/s41598-023-46041-y. Sci Rep. 2023. PMID: 37968310 Free PMC article.
-
Ayahuasca for the Treatment of Depression.Curr Top Behav Neurosci. 2022;56:113-124. doi: 10.1007/7854_2021_277. Curr Top Behav Neurosci. 2022. PMID: 34761362
-
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147. Curr Neuropharmacol. 2024. PMID: 38284341 Free PMC article. Review.
-
N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.Hum Psychopharmacol. 2022 May;37(3):e2835. doi: 10.1002/hup.2835. Epub 2022 Feb 17. Hum Psychopharmacol. 2022. PMID: 35175662 Free PMC article. Review.
-
Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye.Biomedicines. 2022 Apr 26;10(5):997. doi: 10.3390/biomedicines10050997. Biomedicines. 2022. PMID: 35625734 Free PMC article.
References
-
- Alper K. R., Lotsof H. S. (2007). “The use of ibogaine in the treatment of addictions,” in Psychedelic Medicine New Evidence for Hallucinogenic Substances as Treatments Vol. 2 eds Winkelman M. J., Roberts T. B. (Westport, CT: Praeger Publishers; ) 43–66.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
